Michaela Liedtke
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Hematology
- Member, Stanford Cancer Institute
- Assistant Professor - Med Center Line (By courtesy), Pathology
Key Documents
Contact Information
-
Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr CC-2332 MC 5821 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 724-5203
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Hematology
- Cancer> Hematology> Leukemia - Acute and Chronic
- Multiple Myeloma
- Amyloidosis
- Hematology
Administrative Appointments
- Member, Stanford Amyloid Center (2010 - present)
- Member Leukemia Committee, Southwest Oncology Group (2011 - present)
Honors and Awards
- Translational Research Award, Stanford Department of Medicine (2011)
- Young Investigator Award, ASCO (2008)
- Research grant, Hope Street Kids Foundation (2006)
- Methods in Clinical Cancer Research Scholar, ASCO/AACR (2005)
- Fellowship Award, Lymphoma Research Foundation (2004)
- Translational Research Award, Doris Duke Foundation (2004)
Professional Education
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2006) |
| Board Certification: | Hematology, American Board of Internal Medicine (2005) |
| Fellowship: | Stanford University Medical Center CA (2005) |
| Fellowship: | Memorial Sloan-Kettering Cancer Center, NY USA (2004) |
| Residency: | Albert Einstein College of Medicine NY (2002) |
| Medical Education: | Medizinische Hochschule Hannover, Germany (1994) |
Graduate & Fellowship Program Affiliations
Internet Links
Scientific Focus
Current Research Interests
1) Design of phase I/II trials for the treatment of Multiple Myeloma and Amyloidosis
2) Conduct of clinical trials to improve the treatment of patients with acute lymphoblastic leukemia (ALL)
3) Outcomes research using clinical databases for patients with Multiple Myeloma and Amyloidosis
4) Characterization of the molecular mechanism of MLL-induced acute leukemia
Clinical Trials
- Not Recruiting A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
- Recruiting Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
- Recruiting Phase I, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
- Not Recruiting A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
- Recruiting Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Publications
- A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. Leuk Lymphoma. 2013
- AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A. 2013; (24): 9992-7
- Lenalidomide, melphalan and dexamethasone in an immunoglobulin light chain amyloidosis patient population with high rates of advanced cardiac involvement. Haematologica. 2013
- Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013; (1): 11-7
- Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica. 2013; (4): 591-6
- The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. Br J Haematol. 2013; (3): 367-72
Help